Medexus Pharmaceuticals Inc (TSE:MDP) has released an update.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Medexus Pharmaceuticals reported a revenue of $26.3 million for fiscal Q2 2025, with a notable increase in net income to $0.1 million, despite a decline in overall sales. The company’s financial discipline and improvements in manufacturing processes contributed to a rise in Adjusted EBITDA to $6.0 million, showcasing Medexus’s strategic efforts to strengthen its financial position.
For further insights into TSE:MDP stock, check out TipRanks’ Stock Analysis page.